Figure 4: Comparison of platelet-derived microparticle (PMP) counts between CAS patients (during acute and chronic phases) and control subjects. ANOVA: p = 0.03; Bonferroni test (acute versus chronic phases): p = 0.02.All patients with CAS were receiving treatment with calcium channel blocking drugs, which have been reported to inhibit release of platelet-derived microparticles (Rosinska,Lukasik and Kozubski, 2017).